a short review for Yasser...the crooked owners who've colluded to jack the price 60 points beyond outside demand (to periodically squeeze short sellers attracted to overvalued equities) also gotta cover sales if they push the price beyond reason, check it out...
Shares Outstanding: 28.82M
% Held by Insiders: 12.63%
% Held by Institutions: 102.40%
Market Cap: 2,250M
Revenue (ttm): 1.23M
EBITDA (ttm): -67.18M
Net Income Avl to Common (ttm): -68.74M
This stock has become li'l more than a tool for the insiders/institutions/funds to shovel shares back and forth to bump the price in order to trap and loot short sellers. the numbers don't add up. No one is applying affordability to the equation. Using the CEOs guesstimate of 15,000 afflicted with HoFH worldwide (more'n double the FDA estimate of one in a million), based on 2009 IRS statistics roughly one in two hundred Americans could (if they chose) afford a 300K prescription. Course we’re more affluent than most in the world, USA GDP per capita is $49,800 (2012 est.), World GDP per capita is $12,400 (2012 est.), accordingly you’d have to assume a much smaller ratio able to afford it on a worldwide basis, assuming one in a thousand (probably still far too high) persons can afford the prescription (and choose it over less expensive treatments), you’ve a grand total of 15 customers, and 4.5 million in annual revenue.